Chronic Myelogenous Leukemia (CML)

2

Review clinical trials related to Chronic Myelogenous Leukemia (CML). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Participants needed: 99,999
Trial details
Biological sex: AllType: ObservationalSponsor: Center for International Blood and Marrow Transplant ResearchUpdated: Jun 4, 2026Locations: 142
Eligibility criteria

Disorders affecting the hematopoietic system that are inherited, acquired, or re... [+2]

Patients who are receiving only licensed CBUs [+3]

Status: Recruiting

Cord Blood Transplant in Adults With Blood Cancers

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body for transplant, the amount of stem cells transplanted, and how patients are followed during and after transplant.The purpose of this study is to collect information about participant outcomes after CBT following MSK's optimized practice. The researchers will look at outcomes of the CBT treatment such as side effects, disease relapse, GVHD, and immune system recovery after CBT treatment.

Participants needed: 54
Trial details
Phase: Phase 2Age: 21-65Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Sep 8, 2025Locations: 1
Eligibility criteria

Known prior diagnosis of myelodysplasia (MDS) or myeloproliferative disorder (MP... [+32]

Diagnosis of myelofibrosis or other malignancy with moderate-severe bone marrow... [+12]